Chordate Medical AB

13/01/2025

The highly esteemed scientific journal Neurology Journal has published the scientific article on Chordate Medical’s pivotal PM007 registration study on preventive neurostimulation treatment for chronic migraine.

“It is rare for medical technology in a clinical study to demonstrate this level of clarity and significance, and the importance of this publication for the company’s value can hardly be overstated,” says Chordate CEO Anders Weilandt.

The highly esteemed scientific journal Neurology has published the scientific article on Chordate Medical’s pivotal PM007 registration study on preventive...

20/11/2024

Chordate Medical Holding AB announces the outcome of warrants of series TO 8: https://www.chordate.com/mfn_news/chordate-medical-holding-ab-publ-announces-the-outcome-of-warrants-of-series-to-8/

04/11/2024

The exercise period for warrants of series TO 8 in Chordate Medical Holding AB begins today. More info: https://www.chordate.com/mfn_news/the-exercise-period-for-warrants-of-series-to-8-in-chordate-medical-holding-ab-publ-begins-today/

24/10/2024

The first demonstration with Ozilia® Migraine in Saudi Arabia was conducted yesterday at King Abdulaziz Medical City, a National Guard hospital in Jeddah. The company’s distributor, Janin Medical, has been preparing for the launch since this spring – and this marks the first step after receiving market approval from the SFDA (Saudi Food and Drug Authority) a week ago.

The first demonstration with Ozilia® Migraine was conducted yesterday at King Abdulaziz Medical City, a National Guard hospital in Jeddah....

16/10/2024

At investor event Aktieportföljen Live, on October 15th, Chordate CEO Anders Weilandt talked about appointing Partner International Switzerland GmbH as an advisor to find a buyer for the business. Read more and view the full presentation and Q&A:

At investor event Aktieportföljen Live, on October 15th, Chordate CEO Anders Weilandt talked about the appointment of Partner International Switzerland...

15/10/2024

Chordate Medical retains Swiss Advisor to initiate the exit process.

Chordate Medical Holding AB announces the board’s resolution to appoint Partner International Switzerland GmbH as an advisor to find an international buyer for the business. This marks the initiation of the final step in the company’s strategy.

Chordate Medical Holding AB (publ) (”Chordate” or ”The Company”) announces the board’s resolution to appoint Partner International Switzerland GmbH as...

14/10/2024

Chordate Medical receives market authorization for the migraine indication in Saudi Arabia.

Chordate Medical announces that the Saudi Food and Drug Authority (SFDA) has approved the application for market authorization for the...

11/10/2024

On Tuesday, October 15th, at 11:15, Chordate’s CEO Anders Weilandt will participate at the investor event Aktieportföljen Live: https://www.chordate.com/en/chordate-medical-ceo-presents-the-company-and-ozilia-at-aktieportfoljen-live/

03/10/2024

Chordate participates in Feminvest’s investor conference FEARLESS in Stockholm on October 8th.

Chordate Medical non-executive Director and main owner Caroline Lundgren Brandberg will participate in Feminvest’s investor conference “Fearless” in Stockholm on...

02/10/2024

US magazine Wired covers migraine and Chordate’s Ozilia treatment.

The American magazine Wired recently published an article on neuromodulation as an emerging method for treating migraines. Wired describes the...

30/09/2024

Chordate Medical Receives First Order for Ozilia Migraine Treatment from Saudi Arabia.

Chordate Medical has received its first order for the Ozilia migraine treatment from Janin Medical, the company’s distributor in Saudi...

09/09/2024

Updated Kalqyl analysis of Chordate Medical after Q2: “A step closer to fulfilling the market plan”.

https://www.chordate.com/en/kalqyl-in-updated-analysis-of-chordate-medical-after-q2-a-step-closer-to-fulfilling-the-market-plan/